vs
Acadian Asset Management Inc.（AAMI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Acadian Asset Management Inc.的季度营收约是再鼎医药的1.4倍（$172.2M vs $127.1M），再鼎医药同比增速更快（17.1% vs 2.6%），过去两年Acadian Asset Management Inc.的营收复合增速更高（27.6% vs 20.8%）
Acadian Asset Management Inc.是一家总部位于美国马萨诸塞州波士顿的资产管理机构，专注于为全球机构及个人客户提供专业的投资管理解决方案，在资产管理领域拥有成熟的服务经验与市场布局。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AAMI vs ZLAB — 直观对比
营收规模更大
AAMI
是对方的1.4倍
$127.1M
营收增速更快
ZLAB
高出14.5%
2.6%
两年增速更快
AAMI
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $172.2M | $127.1M |
| 净利润 | $34.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 33.3% | -54.6% |
| 净利率 | 20.2% | — |
| 营收同比 | 2.6% | 17.1% |
| 净利润同比 | -18.4% | — |
| 每股收益（稀释后） | $0.97 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAMIZLAB
| Q4 25 | $172.2M | $127.1M | ||
| Q3 25 | $144.2M | $115.4M | ||
| Q2 25 | $127.4M | $109.1M | ||
| Q1 25 | $119.9M | $105.7M | ||
| Q4 24 | $167.8M | $108.5M | ||
| Q3 24 | $123.1M | $101.8M | ||
| Q2 24 | $109.0M | $100.1M | ||
| Q1 24 | $105.7M | $87.1M |
净利润AAMIZLAB
| Q4 25 | $34.7M | — | ||
| Q3 25 | $15.1M | $-36.0M | ||
| Q2 25 | $10.1M | $-40.7M | ||
| Q1 25 | $20.1M | $-48.4M | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $16.9M | $-41.7M | ||
| Q2 24 | $11.0M | $-80.3M | ||
| Q1 24 | $14.6M | $-53.5M |
毛利率AAMIZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率AAMIZLAB
| Q4 25 | 33.3% | -54.6% | ||
| Q3 25 | 18.4% | -42.3% | ||
| Q2 25 | 12.7% | -50.3% | ||
| Q1 25 | 26.6% | -53.3% | ||
| Q4 24 | 38.7% | -62.6% | ||
| Q3 24 | 21.9% | -66.6% | ||
| Q2 24 | 18.9% | -76.0% | ||
| Q1 24 | 21.7% | -80.7% |
净利率AAMIZLAB
| Q4 25 | 20.2% | — | ||
| Q3 25 | 10.5% | -31.2% | ||
| Q2 25 | 7.9% | -37.3% | ||
| Q1 25 | 16.8% | -45.8% | ||
| Q4 24 | 25.3% | — | ||
| Q3 24 | 13.7% | -40.9% | ||
| Q2 24 | 10.1% | -80.2% | ||
| Q1 24 | 13.8% | -61.4% |
每股收益（稀释后）AAMIZLAB
| Q4 25 | $0.97 | $-0.05 | ||
| Q3 25 | $0.42 | $-0.03 | ||
| Q2 25 | $0.28 | $-0.04 | ||
| Q1 25 | $0.54 | $-0.04 | ||
| Q4 24 | $1.11 | $-0.09 | ||
| Q3 24 | $0.45 | $-0.04 | ||
| Q2 24 | $0.29 | $-0.08 | ||
| Q1 24 | $0.37 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $200.0M | — |
| 股东权益账面价值 | — | $715.5M |
| 总资产 | $677.0M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AAMIZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务AAMIZLAB
| Q4 25 | $200.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AAMIZLAB
| Q4 25 | — | $715.5M | ||
| Q3 25 | — | $759.9M | ||
| Q2 25 | — | $791.7M | ||
| Q1 25 | — | $810.8M | ||
| Q4 24 | — | $840.9M | ||
| Q3 24 | — | $667.7M | ||
| Q2 24 | — | $704.2M | ||
| Q1 24 | — | $762.2M |
总资产AAMIZLAB
| Q4 25 | $677.0M | $1.2B | ||
| Q3 25 | $751.4M | $1.2B | ||
| Q2 25 | $672.3M | $1.2B | ||
| Q1 25 | $677.3M | $1.2B | ||
| Q4 24 | $703.2M | $1.2B | ||
| Q3 24 | $555.2M | $985.3M | ||
| Q2 24 | $533.1M | $987.4M | ||
| Q1 24 | $544.9M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | -0.07× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流AAMIZLAB
| Q4 25 | $-2.4M | $-26.0M | ||
| Q3 25 | $-23.9M | $-32.0M | ||
| Q2 25 | $61.6M | $-31.0M | ||
| Q1 25 | $-48.8M | $-61.7M | ||
| Q4 24 | $55.8M | $-55.8M | ||
| Q3 24 | $69.6M | $-26.8M | ||
| Q2 24 | $45.7M | $-42.2M | ||
| Q1 24 | $-40.4M | $-90.1M |
自由现金流AAMIZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率AAMIZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度AAMIZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率AAMIZLAB
| Q4 25 | -0.07× | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | 6.10× | — | ||
| Q1 25 | -2.43× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 4.12× | — | ||
| Q2 24 | 4.15× | — | ||
| Q1 24 | -2.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAMI
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
